Czechia SUKL · July 16, 2026

Information Letter: Tavneos (avakopan) – Recommendation for Withdrawal of EU Marketing Authorisation and Strengthened Hepatic Monitoring Requirements

Original title: Informační dopis – Tavneos (avakopan)

Healthcare professional communication recommending withdrawal of Tavneos (avakopan) marketing authorisation in the EU and tightened liver function monitoring requirements.

Low obligation Product class Pharmaceuticals Czech Republic Pharmacovigilance

Informační dopis pro zdravotnické pracovníky - Tavneos (avakopan) doporučení k zrušení registrace v Evropské unii a zpřísnění požadavků na sledování jaterních funkcí.

Read the official source ↗

Published by Czechia SUKL. HealthSignal links to the original document; the summary above is extracted from the source text.